Skip to main content
VERICI DX PLC logo

VERICI DX PLC — Investor Relations & Filings

Ticker · VRCI ISIN · GB00BM8HZD43 LEI · 213800FI5WE4FVQ3G645 IL Real estate activities
Open in API
Filings indexed 192 across all filing types
Latest filing 2021-08-31 Regulatory Filings
Country GB United Kingdom
Listing IL VRCI

About VERICI DX PLC

https://www.vericidx.com/

Verici Dx is an immuno-diagnostics company developing and commercializing a suite of proprietary tests for the kidney transplant market. The company's platform utilizes artificial intelligence-assisted transcriptomic analysis of RNA signatures to provide data-driven insights to clinicians. These tests are designed to decipher the body's immune response and other biological signals, enabling personalized risk assessment for organ injury, rejection, and graft failure. The goal is to assist clinicians in medical management throughout the transplant process, from pre-transplant to late-stage care, ultimately aiming to improve patient outcomes and long-term graft survival.

Recent filings

Filing Released Lang Actions
Patient enrolment completed
Regulatory Filings Classification · 100% confidence The document begins with 'RNS Number : 1038K' and contains standard boilerplate language referencing 'RNS, the news service of the London Stock Exchange' and 'Financial Conduct Authority'. The content is a brief announcement regarding the completion of patient enrolment for a clinical validation trial for lead products, including quotes from the CEO and contact information for advisers. This format is characteristic of a general regulatory news service announcement, rather than a comprehensive report (like 10-K or IR) or a specific financial event disclosure (like ER or DIV). Since it is a general regulatory announcement that doesn't fit the highly specific categories (like DIRS, MANG, or CAP), the most appropriate fallback category is Regulatory Filings (RNS). The document length (4736 chars) is short, but it is the primary announcement itself, not just an announcement *about* another report, so RPA is less fitting than RNS for this type of general operational update distributed via RNS.
2021-08-31 English
Appointment of Non-executive Director
Board/Management Information Classification · 98% confidence The document is a formal announcement disseminated via RNS (RNS Number: 1046J) from Verici Dx plc. The core content announces the 'Appointment of Non-executive Director' (Lorenzo Gallon). This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of Board/Management Information (MANG). Although it is distributed via RNS, the specific subject matter is not a general regulatory filing or a report publication announcement, but a specific personnel change.
2021-08-19 English
Acceptance to CLIA Program
Regulatory Filings Classification · 100% confidence The document begins with an 'RNS Number' and is dated July 27, 2021. It announces a specific operational milestone: 'Acceptance to CLIA Program' for the US clinical laboratory, which is a significant regulatory step for commercial launch. The text concludes with standard disclaimers referencing 'RNS, the news service of the London Stock Exchange' and the FCA. This format strongly indicates a general regulatory announcement or news service release that does not fit into the more specific categories like 10-K, ER, or DIV. Since it is a general regulatory announcement distributed via RNS and doesn't fit a more precise category (like DIRS, MANG, or CAP), the appropriate fallback classification is Regulatory Filings (RNS). The document length (5353 chars) is substantial enough that it is the primary announcement, not just a brief notice of publication (RPA).
2021-07-27 English
First European Clinical Trial Site Initiated
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and is dated July 20, 2021. It announces a specific operational update: 'Verici expands its clinical trial by opening first site in Europe'. The content details a clinical trial expansion, collaboration with a European hospital, and future data publication timelines. The structure, including the RNS header, the nature of the announcement (a specific, timely operational update), and the closing boilerplate referencing RNS and the London Stock Exchange, strongly indicates this is a general regulatory news service announcement. Since it is not a full financial report (10-K, IR), a specific management change (MANG), or a dividend notice (DIV), the most appropriate classification is the general regulatory announcement category, RNS.
2021-07-20 English
Directorate Change
Board/Management Information Classification · 98% confidence The document is a formal announcement disseminated via RNS (Regulatory News Service) of the London Stock Exchange, indicated by the 'RNS Number' and the concluding boilerplate text referencing RNS and the FCA. The core content announces the 'Death of Director', Dr. Barbara Murphy. This type of announcement, concerning a change in the composition of the Board of Directors or senior management, directly corresponds to the definition of 'Board/Management Information' (MANG). It is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2021-07-01 English
Non-executive Director receives award
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 9050C' and contains information about a Non-Executive Director receiving an award. It is distributed via 'Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange.' This structure strongly indicates a general regulatory announcement or press release that is not a core financial filing (like 10-K, IR, or ER). Since it is a general announcement distributed through the RNS system but explicitly marked as non-regulatory (Reach), the most appropriate fallback category is Regulatory Filings (RNS), as it covers miscellaneous announcements distributed via this channel that don't fit specific categories like Director's Dealing (DIRS) or Management Changes (MANG). While it mentions a director, the core content is an award announcement, not a director's trade or a formal management change.
2021-06-24 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.